1. Global Prevalence of Depressive and Anxiety Symptoms in Children and Adolescents During COVID-19. Nicole Racine et al. JAMA Pediatr. August 09, 2021.
    https://doi.org/10.1001/jamapediatrics.2021.2482
  2. How can the public health impact of vaccination be estimated?. Susy Echeverria-Londono, et al. BMC Public Health. November 09, 2021. https://doi.org/10.1186/s12889-021-12040-9
  3. Informe Técnico N°076-2021, correspondiente a la proyección de escenarios de la tercera ola de COVID-19 en el Perú. Ministerio de Salud. 05 de agosto del 2021. 
    https://caretas.pe/wp-content/uploads/2021/08/Informe-Te%CC%81cnico-3ra-Ola-03.08.2021.pdf
  4. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. Erika Molteni et al. Lancet Child Adolesc Health. August 03, 2021.
    https://doi.org/10.1016/S2352-4642(21)00198-X
  5. Management of COVID-19 ICU-survivors in primary care: - a narrative review. KFR Schmidt et al. BMC Family Pract. July 24, 2021.
    https://doi.org/10.1186/s12875-021-01464-2
  6. Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study. Dominik Menges et al. PLoS ONE. July 12, 2021.
    https://doi.org/10.1371/journal.pone.0254523
  7. Worksite Temperature Screening for COVID-19. Stave, Gregg M. MD et al. Journal of Occupational and Environmental Medicine. April 28, 2021.
    https://doi.org/10.1097/JOM.0000000000002245
  8. Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection The INTERCOVID Multinational Cohort Study. José Villar, MD et al. JAMA Network. April 22, 2021.
    https://doi.org/10.1001/jamapediatrics.2021.1050
  9. Ten scientific reasons in support of airborne transmission of SARS-CoV-2. Trisha Greenhalgh et al. THE LANCET. April 15, 2021.
    https://doi.org/10.1016/S0140-6736(21)00869-2
  10. Infectivity, susceptibility, and risk factors associated with SARS-CoV-2 transmission under intensive contact tracing in Hunan, China. Shixiong Hu et al. Nature. March 09, 2021. 
    https://doi.org/10.1038/s41467-021-21710-6
  11. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Nicholas G. Davies et al. Science. March 03, 2021. 
    https://doi.org/10.1126/science.abg3055
  12. Reações adversas a medicamentos em pacientes com COVID-19 no Brasil: análise das notificações espontâneas do sistema de farmacovigilância brasileiro. José Romério Rabelo Melo et al. Scielo. January 22, 2021. 
    https://doi.org/10.1590/0102-311X00245820
  13. Infectivity of asymptomatic versus symptomatic COVID-19. Andrew A Sayampanathan et al. The Lancet. January 09, 2021. 
    https://doi.org/10.1016/S0140-6736(20)32651-9
  14. The AndroCoV Clinical Scoring for COVID-19 Diagnosis: A Prompt, Feasible, Costless, and Highly Sensitive Diagnostic Tool for COVID-19 Based on a 1757-Patient Cohort. Flavio A. Cadegiani et al. Cureus. January 07, 2020. 
    https://doi.org/10.7759/cureus.12565
  15. Longitudinal increases in childhood depression symptoms during the COVID-19 lockdown. Giacomo Bignardi et al. BMJ. December 09, 2020. 
    http://dx.doi.org/10.1136/archdischild-2020-320372
  16. PROTOCOLO PROFILAXIS Y TRATAMIENTO AMBULATORIO TEMPRANO PARA COVID-19. FLCCC Alliance. December 09, 2020.
    https://covid19criticalcare.com/wp-content/uploads/2020/12/FLCCC-I-MASK-Protocol-v6-2020-12-09-ESPANOL.pdf
  17. Return to sports after COVID-19 infection. Philipp Schellhorn et al. European Heart Journal. December 07, 2020. 
    https://doi.org/10.1093/eurheartj/ehaa448
  18. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Robert M. Cox, Josef D. Wolf & Richard K. Plemper. Nature. December 03, 2020. 
    https://doi.org/10.1038/s41564-020-00835-2
  19. Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China. Shiyi Cao et al. Nature Commnunications. November 20, 2020.
    https://doi.org/10.1038/s41467-020-19802-w
  20. Factores relacionados con el contagio por SARS-CoV-2 en profesionales de la salud en España. Proyecto SANICOVI. María Teresa Moreno-Casbas. ELSEVIER. 2020 November-December. 
    https://doi.org/10.1016/j.enfcli.2020.05.021
  21. Genomic evidence for reinfection with SARS-CoV-2: a case study. Richard L Tillett, PhD, et al. The Lancet. October 12, 2020. 
    https://doi.org/10.1016/S1473-3099(20)30764-7
  22. Cacciapaglia, G., Cot, C. & Sannino, F. Second wave COVID-19 pandemics in Europe: a temporal playbook. Sci Rep 10, 15514 (2020).  
    https://doi.org/10.1038/s41598-020-72611-5
  23. Changes in Adult Alcohol Use and Consequences During the COVID-19 Pandemic in the US. Michael S. Pollard, et al. PhD. JAMA Network Open. September 29, 2020.
    https://dx.doi.org/10.1001%2Fjamanetworkopen.2020.22942
  24. Coronavirus disease 2019 and first-trimester spontaneous abortion: a case-control study of 225 pregnant patients. Stefano Cosma, PhD, et al. Am J Obstet Gynecol. October 07, 2020. 
    https://doi.org/10.1016/j.ajog.2020.10.005 
  25. Prevalence of anxiety and depression symptom, and the demands for psychological knowledge and interventions in college students during COVID-19 epidemic: A large cross-sectional study. Zheng-HeWang et al. ELSEVIER. October 01, 2020. 
    https://doi.org/10.1016/j.jad.2020.06.034
  26. Actualización Epidemiológica: Enfermedad por coronavirus (COVID-19). Organización Panamericana de la Salud. 18 de Septiembre 2020. 
    https://www.paho.org/es/documentos/actualizacion-epidemiologica-enfermedad-por-coronavirus-covid-19-18-septiembre-2020
  27. Facial Masking for Covid-19 — Potential for “Variolation” as We Await a Vaccine. Monica Gandhi, M.D., M.P.H., and George W. Rutherford, M.D. The New England Journal of Medicine. September 08, 2020. 
    https://doi.org/10.1056/NEJMp2026913
  28. Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries. Ali J.Marian. ELSEVIER. Febrero, 2021. 
    https://doi.org/10.1016/j.carpath.2020.107278
  29. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays. World Health Organization. September 11, 2020. 
    https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays
  30. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Denis Y Logunov, DSc, et al. September 04, 2020. 
    https://doi.org/10.1016/S0140-6736(20)31866-3
  31. Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contacts with Patients of COVID-19. Waheed Shouman, et al. August 27, 2020. 
    https://clinicaltrials.gov/ProvidedDocs/61/NCT04422561/Prot_SAP_000.pdf
  32. Risk of COVID-19 in health-care workers in Denmark: an observational cohort study. Prof Kasper Iversen, DMS, et al. August 03, 2020. 
    https://doi.org/10.1016/S1473-3099(20)30589-2
  33. COVID-19. El manejo ambulatorio durante la transmisión comunitaria intensa. César Ticona Huaroto, Máximo M. Espinoza Silva, Eduardo Ticona Chávez. An Fac med. 2020;81(2). 31 de julio del 2020. 
    https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/18406/15460
  34. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. Kizzmekia S. Corbett, et al. NEJM. July 28, 2020. 
    https://doi.org/10.1056/NEJMoa2024671
  35. PLAN DE CONTINGENCIA FAMILIAR PARA DISMINUIR EL RIESGO DE CONTAGIO POR COVID-19. Jannet Ludeña. OMS. Versión Perú. May 2020. 
    http://www.mimp.gob.pe/sinavol/Plan-contingencia-familiar-covid-PRODUCE.pdf
  36. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Pedro M Folegatti, MSc, et al. THE LANCET. July 20, 2020. 
    https://doi.org/10.1016/S0140-6736(20)31604-4
  37. CDC Centers for Disease Control and Prevention: Duration of Isolation and Precautions for Adults with COVID-19. July 17, 2020. 
    https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html
  38. La paradoja de los pacientes COVID-19 que no desarrollan anticuerpos. Danny O. Suclupe Campos. Grupo de investigación en INMUNOLOGÍA y VIROLOGÍA del norte. 16 julio del 2020. 
    https://grupoinmuno-viro.wixsite.com/website/post/la-paradoja-de-los-pacientes-covid-19-que-no-desarrollan-anticuerpos
  39. Vitamin D Sufficiency Reduced Risk for Morbidity and Mortality in COVID-19 Patients. Zhila Maghbooli, et al. The Lancet. July 14, 2020. 
    http://dx.doi.org/10.2139/ssrn.3616008
  40. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. Lisa A. Jackson, et al. NEJM. July 14, 2020.
    https://doi.org/10.1056/NEJMoa2022483
  41. OMS. Transmission of SARS-CoV-2: implications for infection prevention precautions. July 09, 2020. 
    https://www.who.int/publications/i/item/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations 
  42. Coronavirus Disease 2019–COVID-19. Kuldeep Dhama, et al. Clin Microbiol Rev 33:e00028-20. July 09, 2020. 
    https://doi.org/10.1128/CMR.00028-20
  43. Could there be a link between oral hygiene and the severity of SARS-CoV-2 infections?. Victoria Sampson, Nawar Kamona & Ariane Sampson. Br Dent J 228, 971–975 (2020). June 26, 2020. 
    https://doi.org/10.1038/s41415-020-1747-8
  44. Asymptomatic transmission and the infection fatality risk for COVID-19: Implications for school reopening. Sten H Vermund, MD, PhD, Virginia E Pitzer, ScD. Clinical Infectious Diseases, ciaa855. June 25, 2020. 
    https://doi.org/10.1093/cid/ciaa855
  45. The end of social confinement and COVID-19 re-emergence risk. Leonardo López & Xavier Rodó. Nature Human Behaviour volume 4, pages746–755(2020). June 22, 2020. 
    https://doi.org/10.1038/s41562-020-0908-8
  46. Potential Role of Oral Rinses Targeting the Viral Lipid Envelope in SARS-CoV-2 Infection.  Valerie B O’Donnell, David Thomas, Richard Stanton, Jean-Yves Maillard, Robert C Murphy, Simon A Jones, Ian Humphreys, Michael J O Wakelam, Christopher Fegan, Matt P Wise, Albert Bosch, Syed A Sattar. American Physiological Society. May 14, 2020. 
    https://doi.org/10.1093/function/zqaa002
  47. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Quan-Xin Long, et al. June 18, 2020. 
    https://doi.org/10.1038/s41591-020-0965-6
  48. Can existing live vaccines prevent COVID-19?. Konstantin Chumakov, Christine S. Benn, Peter Aaby, Shyamasundaran Kottilil, Robert Gallo. Science  12 Jun 2020: Vol. 368, Issue 6496, pp. 1187-1188. 
    https://doi.org/10.1126/science.abc4262
  49. PNAS Proceedings of the National Academy of Sciences of the United States of America: Identifying airborne transmission as the dominant route for the spread of COVID-19. Renyi Zhang, et al. June 11, 2020. 
    https://doi.org/10.1073/pnas.2009637117
  50. Center for Disease Control and Prevention. How COVID-19 Spreads. June 16, 2020. 
    https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/how-covid-spreads.html
  51. JAMA. Monoclonal Antibodies for Prevention and Treatment of COVID-19. Mary Marovich, John R. Mascola, Myron S. Cohen. June 15, 2020. 
    https://jamanetwork.com/journals/jama/fullarticle/2767383?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jama.2020.10245
  52. American Journal of Respiratory and Critical Care Medicine, Volume 201, Issue 11: An Asymptomatic Patient with COVID-19. June, 2020. 
    https://www.atsjournals.org/doi/10.1164/rccm.202002-0241IM
  53. IEEE, Instituto Español de Estudios Estratégicos. PRIEGO, Alberto. COVID-19, una radiografía de la pandemia. Documento Marco IEEE 6/2020.
    http://www.ieee.es/Galerias/fichero/docs_marco/2020/DIEEEM06_2020ALBPRI_COVIDRadio.pdf
    DATAMEDICA.FISS, como medio de información, no necesariamente se adhiere a  algunas opiniones que se vierten en el presente trabajo.
  54. McMaster University, Canada: Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Derek K Chu, Elie A Akl, Stephanie Duda, Karla Solo, Sally Yaacoub, Holger J Schünemann. The Lancet. Jun 01, 2020.  
    https://doi.org/10.1016/S0140-6736(20)31142-9
  55. Cardiology Centers of the Netherlands. University of Amsterdam: Small droplet aerosols in poorly ventilated spaces and SARS-CoV-2 transmission. Aernout Somsen, Cees van Rijn, Stefan Kooij, Reinout A Bem, Daniel Bonn. Lancet Respir Med. May 27, 2020. 
    (Muestra la importancia de ventilar los espacios).
    https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30245-9/fulltext?utm_source=Coronavirus&utm_campaign=1016650910-EMAIL_CAMPAIGN_2020_05_28_09_42&utm_medium=email&utm_term=0_ce186c567c-1016650910-60632489&mc_cid=1016650910&mc_eid=3250a065bc
  56. National Academy of Sciencies of the Unites States of America: The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission. Publicado el 13 de mayo del 2020. 
    https://doi.org/10.1073/pnas.2006874117
  57. Agencia SINC: Agencia de noticias científicas de la fundación española  para la ciencia y la tecnología. 18 de marzo del 2020. 
    https://www.agenciasinc.es/Noticias/Este-es-el-tiempo-que-dura-el-SARS-CoV-2-en-diversas-superficies
  58. World Health Organization: DRAFT landscape of COVID-19 candidate vaccines. 11 de mayo 2020. 
    https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-194448f6cf724f4c3fbc86a3300ba0b812.pdf?sfvrsn=dfd9da27_1&download=true
  59. Huamaní C, TimanáRuiz R, Pinedo J, Pérez J, Vásquez L. Condiciones estimadas para controlar la pandemia de COVID-19 en escenarios de pre y poscuarentena en Perú. Rev Peru Med Exp Salud Publica. 2020;37(2):195-202. 
    https://doi.org/10.17843/rpmesp.2020.372.5405 
    https://rpmesp.ins.gob.pe/index.php/rpmesp/article/download/5405/3549